Evidence map›Paper›PMID 42708556›Full record

Trial reportAnnals of neurology2026

Non-contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage: An Analysis from ANNEXa-I Trial.

Koji Tanaka, Umberto Pensato, Mohamed Alshamrani, Aristeidis H Katsanos, Pargol Balali, Sucharita Ray, Scott E Kasner, Jan Beyer-Westendorf, Danilo Toni, David J Seiffge and 26 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Koji TanakaDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Umberto PensatoDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID https://orcid.org/0000-0002-4042-4735
Mohamed AlshamraniDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Aristeidis H KatsanosDivision of Neurology, Hamilton Health Sciences, McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.
Pargol BalaliDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sucharita RayDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Scott E KasnerDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0418-6917
Jan Beyer-WestendorfDepartment of Medicine, Division of Thrombosis & Hemostasis, Dresden University Clinic, Dresden, Germany.
Danilo ToniDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
David J SeiffgeDepartment of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0003-3890-3849
Carlos MolinaVall d'Hebron University Hospital, Barcelona, Spain.
David TanneRambam Health Care Campus, Technion, Israel Institute of Technology, Haifa, Israel.
Anna CzłonkowskaSecond Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Arne G LindgrenDepartment of Clinical Sciences Lund, Neurology, Lund University; Department of Neurology, Skåne University Hospital, Lund, Sweden.
Daniel BereczkiSemmelweis University, Budapest, Hungary.
Else C SandsetDepartment of Neurology, Oslo University Hospital and the Norwegian Air Ambulance Foundation, Oslo, Norway.
Georgios TsivgoulisSecond Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece.ORCID https://orcid.org/0000-0002-0640-3797
Hanne ChristensenCopenhagen University Hospital, Bispebjerg Hospital, Copenhagen, Denmark.
Jonathan M CoutinhoDepartment of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
Peter VerhammeUniversity Hospitals Leuven, University of Leuven, Leuven, Belgium.
Pierre AmarencoBichat Claude-Bernard Hospital, Paris, France.
Robin LemmensDepartment of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Leuven, Belgium; Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
Roland VeltkampDepartment of Brain Sciences, Imperial College, London, UK.
Saskia MiddeldorpDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Thompson RobinsonNIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester, UK.
Truman J MillingDell Medical School, University of Texas, Austin, and the University of Houston, Houston, Texas, USA.
Wilfried LangHospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna, Austria.
Vitor Tedium-CruzUniversity of Porto, Porto, Portugal.
Mark CrowtherDivision of Neurology, Hamilton Health Sciences, McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.
Lizhen XuDivision of Neurology, Hamilton Health Sciences, McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.
Mikael KnutssonBiopharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.
Per LadenvallBiopharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.
John W EikelboomDivision of Neurology, Hamilton Health Sciences, McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.
Mukul SharmaDivision of Neurology, Hamilton Health Sciences, McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.
Ashkan ShoamaneshDivision of Neurology, Hamilton Health Sciences, McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.ORCID https://orcid.org/0000-0002-2802-1626
Andrew M DemchukDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this post hoc analysis of the ANNEXa-I trial (n = 434), we evaluated non-contrast computed tomography (NCCT) markers of hematoma expansion (HE) in factor Xa inhibitor (FXai) -associated intracerebral hemorrhage (ICH). At least one NCCT marker was present in 72.1%, and HE (≥12.5 mL or ≥ 35% increase in hematoma volume) occurred in 31.8%. Heterogeneous density, hypodensity, and the black hole sign were independently associated with HE. The effect of andexanet on HE was generally consistent across NCCT marker subgroups. These findings support the utility of NCCT markers for identifying patients at high risk of HE in FXai-associated ICH. ANN NEUROL 2026;100:979-983.

Indexed as

Cerebral HemorrhageFactor Xa InhibitorsHematomaTomography, X-Ray ComputedAgedFactor XaFemaleHumansMaleMiddle AgedRecombinant ProteinsFactor XaFactor Xa InhibitorsPRT064445Recombinant Proteins

Identifiers

PMID42708556
PMCPMC13688066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.